Back to top
more

AbbVie (ABBV)

(Delayed Data from NYSE)

$196.30 USD

196.30
3,970,192

-2.25 (-1.13%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $196.54 +0.24 (0.12%) 7:56 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (90 out of 246)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.

Zacks Equity Research

AbbVie (ABBV) Submits NDA for Next-Gen HCV Combo in US

by Zacks Equity Research

AbbVie Inc. (ABBV) announced that it has submitted a New Drug Application (NDA) to the FDA for its pan-genotypic regimen of glecaprevir/pibrentasvir (G/P).

    Sheraz Mian headshot

    Analyst Reports for Union Pacific, AbbVie & U.S. Bancorp

    by Sheraz Mian

    Today's Research Daily features new research reports on 16 major stocks, including AbbVie (ABBV), Union Pacific (UNP) and U.S. Bancorp (USB).

      Zacks Equity Research

      Roche (RHHBY) to Terminate Pacifica Bioscience Agreement

      by Zacks Equity Research

      Roche Holding AG (RHHBY) announced that it intends to terminate its agreement with Pacifica Bioscience.

        Zacks Equity Research

        Gilead to Pay Merck $2.5B in HCV Patent Dispute, Stock Falls

        by Zacks Equity Research

        Gilead (GILD) has been ordered to pay $2.5 billion in royalties to Merck (MRK) in the largest patent infringement dispute in the history of the U.S.

          Zacks Equity Research

          Roche/AbbVie's Leukemia Drug Venclyxto Gains EU Approval

          by Zacks Equity Research

          Roche (RHHBY) and AbbVie's (ABBV) Venclyxto has gained EU approval for the treatment of appropriate patients with hard-to-treat chronic lymphocytic leukemia.

            Zacks Equity Research

            AbbVie (ABBV) Presents Impressive Imbruvica Data at ASH

            by Zacks Equity Research

            AbbVie Inc. (ABBV) and partner Janssen, Johnson & Johnson's (JNJ) pharmaceuticals subsidiary, presented encouraging results on their cancer drug Imbruvica at the annual meeting of the American Society of Hematology.

              Zacks Equity Research

              Amgen/Allergan File for EU Approval of Avastin Biosimilar

              by Zacks Equity Research

              Amgen Inc. (AMGN), along with partner Allergan plc. (AGN), announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for ABP 215.

                Zacks Equity Research

                AbbVie Crohn's Disease Drug Gets Orphan Drug Status in U.S.

                by Zacks Equity Research

                AbbVie Inc. (ABBV) announced that the FDA has granted Orphan Drug Designation to its investigational IL-23 inhibitor, risankizumab (ABBV-066; formerly BI 655066), for the treatment of Crohn's disease in pediatric patients.

                  Zacks Equity Research

                  Momenta/Shire's Humira Biosimilar Meets Study Objective

                  by Zacks Equity Research

                  Momenta (MNTA) announced positive data from a phase III study on M923 for the treatment of moderate-to-severe chronic plaque psoriasis.

                    Zacks Equity Research

                    The Zacks Analyst Blog Highlights: Amgen, Cisco, NextEra Energy, AbbVie and eBay

                    by Zacks Equity Research

                    The Zacks Analyst Blog Highlights: Amgen, Cisco, NextEra Energy, AbbVie and eBay

                      Sheraz Mian headshot

                      Top Research Reports for Cisco, Amgen & NextEra Energy

                      by Sheraz Mian

                      Today's Research Daily features new research reports on 16 major stocks, including Amgen (AMGN), Cisco (CSCO) and NextEra Energy (NEE).

                        Arpita Dutt headshot

                        Pharma Industry Outlook - November 2016

                        by Arpita Dutt

                        It's been a rough year for pharma and biotech stocks, with media and political focus on the high price of drugs, mixed performance results, slower-than-expected new product launches and increasing competition.

                          Mark Vickery headshot

                          Timeout from Q3 Earnings: GDP +2.9%

                          by Mark Vickery

                          With GDP at 2.9% in Q3 (first read), we are seeing a snap-back from below-trend growth earlier in the year.

                            Sheraz Mian headshot

                            Stock Research Reports for Amazon, Boeing & MasterCard

                            by Sheraz Mian

                            Today's Research Daily features new research reports on 16 major stocks, including Amazon (AMZN), MasterCard (MA) and Boeing (BA).

                              Tracey Ryniec headshot

                              How Value Investors Can Buy Growth

                              by Tracey Ryniec

                              Value and growth is a magical combination. Here???s how to get it.

                                Sheraz Mian headshot

                                Top Research Reports for Morgan Stanely, Union Pacific & AbbVie

                                by Sheraz Mian

                                Today's must-read reports are for AbbVie (ABBV), Morgan Stanley (MS) and Union Pacific (UNP).

                                  Zacks Equity Research

                                  5 Biotech Stocks to Bet on This Earnings Season

                                  by Zacks Equity Research

                                  The happening biotech sector should be a good bet for investors.

                                    Zacks Equity Research

                                    Stock Market News for April 07, 2016

                                    by Zacks Equity Research

                                    Benchmarks closed in the green on Wednesday following gains in biotech and energy stocks